Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of S-892216 in healthy adults for COVID-19-related development
jRCT2031230082Phase 1Active, not recruiting
- Sponsor
- Shionogi & Co., Ltd.
- Start
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1 trial of S-892216 in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Shionogi & Co., Ltd. Primary endpoints: Adverse events, Physical examination and 7 more. Started May 2023; status: active, not recruiting.
02
Drugs
S-892216
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on jRCT2031230082.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230082.